MedTrace Logo

Comparing Population Cessation Services

NCT01566994 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2500

Last updated 2013-09-17

No results posted yet for this study

Summary

If the treatment combining Motivation Enhancement, Reduction Counseling, Nicotine Replacement Therapy and Transtheoretical tailored interventions produces an increasing treatment trajectory, it will produce unprecedented impacts with unmotivated smokers specifically and population cessation generally. These recruitment and intervention strategies require limited resources from health care providers and could be readily disseminable to other health care systems for application with populations of smokers, especially unmotivated smokers who have been understudied and underserved.

Conditions

Interventions

BEHAVIORAL

TTM Tailored

This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages

BEHAVIORAL

Motivational Enhancement Therapy

This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.

BEHAVIORAL

Integrated Treatment

This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.

Sponsors & Collaborators

  • University of Rhode Island

    lead OTHER

Principal Investigators

  • James O Prochaska, Ph.D. · Univeristy of Rhode Island

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01566994 on ClinicalTrials.gov